Cures Acceleration Network
The Cures Acceleration Network (CAN) was authorized to advance the development of high need cures and reduce significant barriers between research discovery and clinical trials. To achieve these objectives, CAN provides NCATS with new flexibilities in its funding authorities.
Under CAN, NCATS may make large grant awards of up to $15 million per fiscal year, partnership awards that require 1:3 matching funds, and flexible research awards using the special funding mechanism called other transactions (OT), which allows projects to be actively and aggressively managed by using mechanisms similar to those used by the Defense Advanced Research Projects Agency at the U.S. Department of Defense. CAN investments will be guided by the CAN Review Board.
At NCATS, CAN will fund a variety of initiatives designed to address scientific and technical challenges that impede transitional research. Based upon available funds in fiscal year 2013, CAN will support the following activities:
IOM Workshop on CAN
As requested by Congress, NCATS contracted with the Institute of Medicine (IOM) to host a two-day workshop to discuss the authorities provided to NCATS by the recently authorized Cures Acceleration Network (CAN). “Maximizing the Goals of the Cures Acceleration Network to Accelerate the Development of New Drugs and Diagnostics: A Workshop” was held on June 4-5, 2012.